A ALIMENTARY TRACT AND METABOLISM
|
|
B BLOOD AND BLOOD FORMING ORGANS
|
|
C CARDIOVASCULAR SYSTEM
|
|
D DERMATOLOGICALS
|
|
G GENITO URINARY SYSTEM AND SEX HORMONES
|
|
H SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS
|
|
J ANTIINFECTIVES FOR SYSTEMIC USE
|
|
L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
|
L01 ANTINEOPLASTIC AGENTS
|
L01A ALKYLATING AGENTS
|
L01B ANTIMETABOLITES
|
L01C PLANT ALKALOIDS AND OTHER NATURAL PRODUCTS
|
L01D CYTOTOXIC ANTIBIOTICS AND RELATED SUBSTANCES
|
L01E PROTEIN KINASE INHIBITORS
|
L01EA BCR-ABL tyrosine kinase inhibitors [DG:DG03161]
|
L01EB Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors [DG:DG03162]
|
L01EC B-Raf serine-threonine kinase (BRAF) inhibitors [DG:DG03159]
|
L01ED Anaplastic lymphoma kinase (ALK) inhibitors [DG:DG03136]
|
L01EE Mitogen-activated protein kinase (MEK) inhibitors [DG:DG03137]
|
L01EF Cyclin-dependent kinase (CDK) inhibitors [DG:DG03138]
|
L01EG Mammalian target of rapamycin (mTOR) kinase inhibitors [DG:DG03160]
|
L01EH Human epidermal growth factor receptor 2 (HER2) tyrosine kinase inhibitors [DG:DG03158]
|
L01EJ Janus-associated kinase (JAK) inhibitors
|
L01EK Vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitors
|
L01EL Bruton's tyrosine kinase (BTK) inhibitors [DG:DG02022]
|
L01EM Phosphatidylinositol-3-kinase (Pi3K) inhibitors [DG:DG03139]
|
L01EN Fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitors
|
L01EX Other protein kinase inhibitors
|
L01EX01 Sunitinib [DG:DG00712]
|
L01EX02 Sorafenib [DG:DG00713]
|
L01EX03 Pazopanib
|
L01EX04 Vandetanib
|
L01EX05 Regorafenib [DG:DG00720]
|
L01EX06 Masitinib
|
L01EX07 Cabozantinib [DG:DG01670]
|
L01EX08 Lenvatinib [DG:DG01362]
|
L01EX09 Nintedanib [DG:DG01374]
|
L01EX10 Midostaurin
|
L01EX11 Quizartinib [DG:DG01364]
|
D09955 Quizartinib (USAN/INN)
D09956 Quizartinib dihydrochloride (USAN) <JP/US>
|
L01EX12 Larotrectinib [DG:DG02923]
|
L01EX13 Gilteritinib [DG:DG01948]
|
L01EX14 Entrectinib
|
L01EX15 Pexidartinib [DG:DG02960]
|
L01EX17 Capmatinib [DG:DG02081]
|
L01EX18 Avapritinib
|
L01EX19 Ripretinib
|
L01EX21 Tepotinib [DG:DG03087]
|
L01EX22 Selpercatinib
|
L01EX23 Pralsetinib [DG:DG03223]
|
L01EX24 Surufatinib
|
L01EX25 Umbralisib [DG:DG02988]
|
L01EX26 Sitravatinib [DG:DG03045]
|
L01EX27 Capivasertib
|
L01F MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES
|
L01X OTHER ANTINEOPLASTIC AGENTS
|
L02 ENDOCRINE THERAPY
|
L03 IMMUNOSTIMULANTS
|
L04 IMMUNOSUPPRESSANTS
|
|
M MUSCULO-SKELETAL SYSTEM
|
|
N NERVOUS SYSTEM
|
|
P ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS
|
|
R RESPIRATORY SYSTEM
|
|
S SENSORY ORGANS
|
|
V VARIOUS
|